View Older Stories View More Recent Stories
-
Cantor Fitzgerald Reiterates Overweight Rating on Summit Therapeutics plc (SMMT) After Management Meet
-
Summit Therapeutics (SMMT) Tops Q3 EPS by 4c
-
Summit Therapeutics plans to submit BLA for cancer drug in Q4 2025
-
Summit Therapeutics launches phase III colorectal cancer trial
-
UBS Reiterates Buy Rating on Summit Therapeutics plc (SMMT)
-
Why UBS says Q4 is eventful for SMID oncology stocks
-
Citi Opens 30-Day Upside Catalyst Watch on Summit Therapeutics plc (SMMT)
-
Summit presents lung cancer trial data at ESMO 2025
-
Barclays Starts Summit Therapeutics plc (SMMT) at Underweight
-
H.C. Wainwright Reiterates Buy Rating on Summit Therapeutics plc (SMMT)
-
Citizens JMP Reiterates Market Outperform Rating on Summit Therapeutics plc (SMMT)
-
Summit Therapeutics (SMMT) call put ratio 1.9 calls to 1 put amid wide price movement
-
Akeso reports improved survival data for cancer drug ivonescimab
-
H.C. Wainwright Reiterates Buy Rating on Summit Therapeutics plc (SMMT)
-
Citizens JMP Reiterates Market Outperform Rating on Summit Therapeutics plc (SMMT)
-
Guggenheim Starts Summit Therapeutics plc (SMMT) at Buy
-
H.C. Wainwright Reiterates Buy Rating on Summit Therapeutics plc (SMMT)
-
Summit Therapeutics plc (SMMT) PT Raised to $50 at H.C. Wainwright, 'Time to own SMMT'
-
TD Cowen on Summit Therapeutics plc (SMMT): 'Stat Sig Overall Survival In Akeso's HARMONi-A Bodes Well For Summit's HARMONi'
-
UBS Reiterates Buy Rating on Summit Therapeutics plc (SMMT)
-
Piper Sandler Starts Summit Therapeutics plc (SMMT) at Neutral
-
Citizens JMP Reiterates Market Outperform Rating on Summit Therapeutics plc (SMMT)
-
Summit Therapeutics plc (SMMT) PT Raised to $34 at Evercore ISI
-
Summit Therapeutics (SMMT) Misses Q2 EPS by 3c
-
Cantor Fitzgerald Reiterates Overweight Rating on Summit Therapeutics plc (SMMT)
-
Summit Therapeutics (SMMT) Is Said In Talks For $15 Billion Partnership With Astra (AZN) - Bloomberg
-
H.C. Wainwright Reiterates Buy Rating on Summit Therapeutics plc (SMMT)
-
UBS Starts Summit Therapeutics plc (SMMT) at Buy
-
Clear Street Starts Summit Therapeutics plc (SMMT) at Buy
-
Revolution Medicines (RVMD) and Summit Therapeutics (SMMT) Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors
-
Cantor Fitzgerald Reiterates Overweight Rating on Summit Therapeutics plc (SMMT)
-
Leerink Partners Starts Summit Therapeutics plc (SMMT) at Underperform
-
Cantor Fitzgerald Reiterates Overweight Rating on Summit Therapeutics plc (SMMT)
-
H.C. Wainwright Reiterates Buy Rating on Summit Therapeutics plc (SMMT)
-
Citizens JMP Reiterates Market Outperform Rating on Summit Therapeutics plc (SMMT)
-
Summit Therapeutics (SMMT): Ivonescimab Plus Chemo Demonstrates Statistically Significant and Clinically Meaningful Improvement in PFS in Patients with EGFR-Mutant NSCLC
-
Citizens JMP: Standard of Care Modifying Regimens at ASCO 2025
-
Citizens JMP shares updates on cancer treatment stocks
-
Clear Street Starts Summit Therapeutics plc (SMMT) at Buy
-
TD Cowen Upgrades Summit Therapeutics plc (SMMT) to Buy
-
Cantor Fitzgerald Reiterates Overweight Rating on Summit Therapeutics plc (SMMT)
-
Summit Therapeutics (SMMT) Tops Q1 EPS by 2c
-
H.C. Wainwright Reiterates Buy Rating on Summit Therapeutics plc (SMMT)
-
Summit Therapeutics (SMMT) options active on volume of 49K contracts
-
Citizens JMP Reiterates Market Outperform Rating on Summit Therapeutics plc (SMMT)
-
Summit Therapeutics (SMMT) to Resume Trading at 3:30 p.m.
-
Summit Therapeutics (SMMT): Interim OS Analysis Requested from Chinese Health Authorities Shows Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive A
-
Summit Therapeutics (SMMT) Halted, News Pending
-
Summit Therapeutics (SMMT) Halted on Volatility, Down 34%
-
BioNTech SE (BNTX) Hits Low, Down 8%, Summit Therapeutics (SMMT) Falls 18.5%

